



April 27, 2021
JCR Pharmaceuticals Co., Ltd.

Translation

Notice on Change of Representative Directors

Apr. 27, 2021 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that at the Board of Directors meeting held today, it has decided on the following changes in the Representative Directors.

Please note that the change of Representative Directors will be subject to approval at the Ordinary General Meeting of Shareholders and the Board of Directors meeting both scheduled for June, 2021.

Retiring Representative Director (effective June, 2021)

Hiroshi Yoshimoto (current position: Representative Director, Senior Vice President,
Head of Production Division and Executive Director, Production Division)
Mr. Yoshimoto will be appointed “Senior Advisor” at a Board Meeting as scheduled on June, 2021.

<Reference>

Members of the Board of Internal Directors (Planned after a Board Meeting on June, 2021)

Title	Name	Areas of responsibility/ Concurrent position
Representative Director and Chairman, President & CEO	Shin Ashida	-
Senior Vice President	Toru Ashida	Sales and Administration Executive Director, Sales Division
Vice President	Mathias Schmidt, PD, Ph.D.	Clinical Development, Global Business Strategy and Business Development ArmaGen, Inc. CEO JCR USA, Inc. President and CEO
Vice President	Hiroyuki Sonoda, Ph.D.	Research and Corporate Strategy Executive Director, Research Division
Senior Executive Director	Yoshio Hiyama, Ph.D.	Production and Quality Assurance Executive Director, Production Division

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 45-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

###